Organigram (NASDAQ:OGI - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.02), Zacks reports. Organigram had a negative return on equity of 11.68% and a negative net margin of 28.58%.
Organigram Trading Down 4.8 %
Shares of OGI traded down $0.07 during midday trading on Friday, hitting $1.29. 1,720,313 shares of the company's stock traded hands, compared to its average volume of 872,673. The stock has a market capitalization of $162.12 million, a price-to-earnings ratio of -3.36 and a beta of 1.00. Organigram has a 1 year low of $1.27 and a 1 year high of $2.91. The firm's fifty day moving average is $1.56 and its 200-day moving average is $1.66.
About Organigram
(
Get Free Report)
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
Read More
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
